Latest News

• share
• favorite_border

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.

• share
• favorite_border

A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.

• share
• favorite_border

A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CTCs), a form of liquid biopsy, was independently associated with melanoma relapse, suggesting CTC assessment may be useful in identifying patients at risk for relapse who could benefit from more aggressive therapy following primary treatment.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center have shown that a decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population and results in informed decisions about lung cancer screening.

• share
• favorite_border

Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor.

• share
• favorite_border

Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas. Findings may create immunotherapy options for lymphomas caused by CREBBP mutations.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

• share
• favorite_border

A study combining low-dose chemotherapy with a monoclonal antibody is effective for older patients with Philadelphia chromosome-negative ALL.

• share
• favorite_border

A one-year follow-up study revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) .

• share
• favorite_border

A Phase II study pairing azacitidine with enasidenib boosts complete remission in patients with AML with IDH2 mutations.

• share
• favorite_border

Patients who had acupuncture during radiation reported less dry mouth symptoms up to 12 months after treatment

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes, TBK1, also can fuel cancer development and suppress immune response to the disease.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center will honor business entrepreneur and philanthropist Jim Crane, owner and chairman of the Houston Astros, at A Conversation With a Living Legend®, 7 p.m. Dec. 11 at the Hilton Americas.

• share
• favorite_border

Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of Texas MD Anderson Cancer Center found men who seek treatment at a multidisciplinary (MultiD) prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines.

• share
• favorite_border

Prostate cancer that spreads to the bone triggers the destruction of bone tissue that thwarts the effectiveness of immune checkpoint inhibitors. Research points to anti-CTLA-4 and anti-TGF-B combination to protect T cells.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.

• share
• favorite_border

MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.

• share
• favorite_border

MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.

• share
• favorite_border

Ziopharm and MD Anderson have announced a new research and development agreement to develop novel T-cell therapies using engineered T-cell receptors for solid tumors.

• share
• favorite_border

Seven business and community leaders from across the nation join MD Anderson Cancer Center Board of Visitors.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Varian today announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.

• share
• favorite_border

The North Texas A Conversation With a Living Legend® will honor Los Angeles Dodgers starting pitcher Clayton Kershaw in an interview with CBS News' Bob Schieffer. The luncheon benefits the Moon Shots Program®.

• share
• favorite_border

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

• share
• favorite_border

In the largest smoking cessation study of cancer patients to date, researchers from The University of Texas MD Anderson Cancer Center found that comprehensive tobacco treatment can help cancer patients successfully quit and abstain from smoking.

• share
• favorite_border

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study

• share
• favorite_border

MD Anderson has awarded Sheryl Harris, C.N.A., the Julie and Ben Rogers Award for Excellence in Patient Care. The annual award recognizes employees who demonstrate excellence and dedication to MD Anderson’s mission to end cancer.

• share
• favorite_border

MD Anderson and Houston Dynamo unite to kick childhood cancer. MD Anderson faculty and staff, pediatric patients, and their families to raise awareness of childhood cancers at Houston Dynamo vs Orlando City Soccer Club game on Saturday, September 21.

• share
• favorite_border

An oncogene, UPS21, has been confirmed as a frequently amplified gene in pancreatic ductal adenocarcinoma, the most common and often lethal form of pancreatic cancer. The discovery could lead to new treatment options.

• share
• favorite_border

MD Anderson's status as one of 51 comprehensive cancer centers was renewed for $55 million over five years by the National Cancer Institute.

• share
• favorite_border

Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.

• share
• favorite_border

MD Anderson researchers find tumor microbiome influences immune response and patient survival in pancreatic cancer. Study points to fecal transplant as possible treatment.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a groundbreaking ceremony. The expansion will more than double the center’s size to more than 160,000 square feet – almost the size of three football fields – allowing more patients greater access to the most advanced and precise form of radiation therapy.

• share
• favorite_border

A Phase II clinical trial led by MD Anderson found that treatment with the FGFR inhibitor erdafitinib was effective in 40% of patients with metastatic bladder cancers marked by FGFR3 mutations. The trial results led to FDA approval of the drug.

• share
• favorite_border

Discovery shows how difficult-to-treat prostate cancer evades immune system and reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs.

• share
• favorite_border

A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma, the most common form of liver cancer.

• share
• favorite_border

The tobacco industry’s court-ordered anti-smoking advertisements reached just 40.6% of U.S. adults and 50.5% of current smokers in 2018, according to new research from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking it, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Cell.

• share
• favorite_border

Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).

• share
• favorite_border

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center applauds the Texas Legislature today for passing Senate Bill 21, which raises the minimum legal sale age for all tobacco products from 18 to 21.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today named David Jaffray, Ph.D., as its first-ever chief technology and digital officer. Jaffray will begin his new duties overseeing MD Anderson’s Information Services division and Information Security department in late summer. He also will hold a faculty appointment as professor of Radiation Physics with a joint appointment in Imaging Physics.

• share
• favorite_border

A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center has named eight researchers to the fourth annual class of Andrew Sabin Family Fellows. Each researcher will receive $100,000 in funding over two years thanks to a $30 million endowment established by the Andrew Sabin Family Foundation, based in East Hampton, New York.